Merck Reports Results for Keytruda (pembrolizumab) in P-III Trial as an Adjuvant Therapy for Urothelial Carcinoma
Shots:
- The P-III (AMBASSADOR/KEYNOTE-123) trial evaluates Keytruda (200mg, IV, Q3W) as adjuvant therapy vs observation in patients (n=702) with localized MIUC & locally advanced resectable UC. The dual 1EPs of the study were OS & DFS whereas the 2EPs include OS, DFS & safety
- At median follow up of 22.3mos., the study depicted a statistically significant & clinically meaningful improvement in DFS with a 31% reduction in risk of recurrence or death & an mDFS of 29mos. vs 14mos. The dual 1EP of OS did not reach statistical significance & was further analyzed
- Additionally, at a median follow-up of 36.9mos., the study showed a mOS was 50.9mos. vs 55.8mos. The safety data was consistent with the previously reported studies
Ref: Merck | Image: Merck
Related News:- Merck Reports US FDA’s Approval of Keytruda + Chemoradiotherapy for Treating FIGO 2014 Stage III-IVA Cervical Cancer
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Shivani is a content writer at PharmaShots. She has a keen interest in recent innovations in the life sciences industry. She covers news related to Product approvals, clinical trial results, and updates. She can be contacted at connect@pharmashots.com.
